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Abstract
Rationale Anecdotally, both acute and chronic cannabis
use have been associated with apathy, amotivation, and
other reward processing deficits. To date, empirical sup-
port for these effects is limited, and no previous studies
have assessed both acute effects of Δ-9-tetrahydrocan-
nabinol (THC) and cannabidiol (CBD), as well as asso-
ciations with cannabis dependence.
Objectives The objectives of this study were (1) to examine
acute effects of cannabis with CBD (Cann + CBD) and
without CBD (Cann-CBD) on effort-related decision-making
and (2) to examine associations between cannabis depen-
dence, effort-related decision-making and reward learning.
Methods In study 1, 17 participants each received three acute
vaporized treatments, namely Cann-CBD (8 mg THC), Cann
+ CBD (8 mg THC + 10 mg CBD) and matched placebo,
followed by a 50 % dose top-up 1.5 h later, and completed
the Effort Expenditure for Rewards Task (EEfRT). In study 2,
20 cannabis-dependent participants were compared with 20
non-dependent, drug-using control participants on the
EEfRT and the Probabilistic Reward Task (PRT) in a non-
intoxicated state.
Results Cann-CBD reduced the likelihood of high-effort
choices relative to placebo (p = 0.042) and increased sensitiv-
ity to expected value compared to both placebo (p = 0.014)
and Cann + CBD (p = 0.006). The cannabis-dependent and
control groups did not differ on the EEfRT. However, the
cannabis-dependent group exhibited a weaker response bias
than the control group on the PRT (p = 0.007).
Conclusions Cannabis acutely induced a transient
amotivational state and CBD influenced the effects of
THC on expected value. In contrast, cannabis depen-
dence was associated with preserved motivation along-
side impaired reward learning, although confounding
factors, including depression, cannot be disregarded.
This is the first well powered, fully controlled study
to objectively demonstrate the acute amotivational ef-
fects of THC.
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Introduction
The endocannabinoid system, which includes the
cannabinoid-1 (CB1) and cannabinoid-2 (CB2) receptors
and their endogenous ligands, is putatively involved in reward
processing and addiction (Curran et al. 2016; Maldonado et al.
2006; Parsons and Hurd 2015). Δ-9-Tetrahydrocannabinol
(THC), the main active compound in cannabis, is a CB1 re-
ceptor partial agonist (Petitet et al. 1998), whichmaymodestly
increase dopamine release in the human striatum (Bossong
et al. 2015). Dopamine is considered critical in various reward
processes (Berridge and Robinson 1998; Schultz et al. 1997).
Individuals who met DSM-IV criteria for cannabis depen-
dence or abuse showed reduced striatal dopamine synthesis
capacity (Bloomfield et al. 2014a), which was negatively cor-
related with their apathy scores (Bloomfield et al. 2014b).
However, other studies have shown no difference between
cannabis users and non-users in dopamine receptor density
(Albrecht et al. 2013; Sevy et al. 2008; Stokes et al. 2009;
Urban et al. 2012). In terms of alterations to the
endocannabinoid system, cannabis dependence has been as-
sociated with reduced levels of CB1 receptors (D’Souza et al.
2015; Hirvonen et al. 2012) and reduced anandamide levels in
cerebrospinal fluid (Morgan et al. 2013b).
Cannabis contains many cannabinoids, other than THC. Of
particular interest is cannabidiol (CBD) which has a complex
mode of action, including inhibition of the metabolism and
reuptake of anandamide, inhibition of adenosine uptake,
agonism of the 5-HT1a receptor (McPartland et al. 2015) and
agonism at the GPR55 receptor (Ryberg et al. 2007). Acute
THC has dose-related amnestic (Curran et al. 2002), psychotic
(Morrison et al. 2009) and anxiogenic (Morrison et al. 2009)
effects. CBD has been shown to attenuate or block these neg-
ative effects (Bhattacharyya et al. 2010; Englund et al. 2013;
Morgan et al. 2010b). Furthermore, CBDmay have some anti-
addictive properties in animals and humans ( Morgan et al.
2010a, 2013a; Ren et al. 2009), and use of high-THC/low-
CBD cannabis was especially predictive of cannabis depen-
dence, compared with other types of cannabis (Freeman and
Winstock 2015). Given these opposing pharmacological and
psychological effects of THC and CBD, we hypothesized that
CBD may buffer the effects of THC on reward processing.
Historically, cannabis use has been associated with reduced
motivation (McGlothlin and West 1968). Early, poorly con-
trolled studies into the acute effects of cannabis found both
amotivational (Miles et al. 1974) and null (Mendelson et al.
1976) effects. More recently, both pro-motivational (Foltin
et al. 1990) and amotivational (Cherek et al. 2002) effects have
been reported. However, the former study did not provide tradi-
tional rewards (e.g. money, food) in return for work, preferred
work activities were earned instead. Furthermore, the latter
study had a sample of only five participants. Hence, there is
very little well-conducted, empirical research into the acute
effects of cannabis on motivation to earn rewards. Moreover,
to the authors’ knowledge, no one has examined the effects of
CBD on motivational processing in humans.
Early studies of chronic effects of cannabis found no dif-
ference when comparing heavy with light cannabis users on
fixed ratio button-pressing tasks for rewards (Mello and
Mendelson 1985; Mendelson et al. 1976). Survey data has
also failed to demonstrate a link between long-term cannabis
use and amotivation (Barnwell et al. 2006; Musty and Kaback
1995), although cannabis use has been shown to predict an-
hedonia (Bovasso 2001). Daily, adolescent cannabis users had
a lower motivation for monetary reward than non-users, al-
though comorbid mental health problems and other drug use
were not reported and may have confounded group differ-
ences (Lane et al. 2005). Studies that have investigated antic-
ipatory BOLD response for monetary reward, thought to be an
indicator of intact reward processing, have found opposing
results, with one showing reduced (van Hell et al. 2010) and
another showing enhanced (Nestor et al. 2010) striatal activa-
tion in dependent cannabis users compared to healthy
controls.
Much of the research concerning the psychopharmacology
of reward processing has focused on dopamine. In the past,
learning about rewards (Schultz et al. 1997), vigour of
responding (Niv et al. 2007), incentive-salience attribution
(Flagel et al. 2011) and the pleasure taken from reward con-
sumption (Small et al. 2003; Volkow et al. 1997) have all been
linked to dopamine. Two key aspects of reward processing are
effort-related decision-making (i.e. motivation) and reward
learning, which have been operationalized in humans using
the well-validated Effort Expenditure for Rewards Task
(EEfRT) (Treadway et al. 2009) and Probabilistic Reward
Task (Pizzagalli et al. 2005). Performance on both of these
tasks has been investigated with regard to dopaminergic func-
tioning (Pizzagalli et al. 2008; Wardle et al. 2011; Treadway
et al. 2012b), suggesting that enhanced extracellular dopamine
levels improves motivation (Wardle et al. 2011) and a reduc-
tion in phasic dopamine firing impairs reward learning
(Pizzagalli et al. 2008). However, performance on neither task
has been manipulated using cannabinoid drugs or correlated
with cannabis dependence, despite the claims that cannabis
use is associated with amotivation and reward processing
impairments.
Across two experiments, we first tested the acute effects of
cannabis without CBD (Cann-CBD) and with CBD (Cann +
CBD) on effort-related decision-making. Second, we investi-
gated associations between cannabis dependence, effort-
related decision-making and reward learning. We hypothe-
sized that
1. Cann-CBD would reduce motivation.
2. This effect would be weaker following Cann + CBD, i.e.
CBD would buffer the amotivational effects of THC.
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3. Cannabis dependence would be associated with reduced
motivation and reward learning.
Study 1
Methods
A repeated measures, placebo-controlled, double-blind design
was used to compare Cann-CBD, Cann + CBD and placebo.
Participants were randomly allocated to one of three treatment
order schedules, which were based on a Latin Square design.
Seventeen participants1 (9 women) took part in the study; this
sample size was adequately powered to detect drug × task
interactions in a three-way crossover of d-amphetamine using
the EEfRT (Wardle et al. 2011).
Inclusion criteria were as follows: aged between 18 and 70,
smoked cannabis 3 times/week or less and have smoked can-
nabis 4 or more times in the last year. Exclusion criteria were
as follows: regular negative experiences when smoking can-
nabis, alcohol use >5 days/week, other illicit drug use >2
times/month, current or history of psychosis and MRI
contraindications.
Participants were recruited through word of mouth and all
provided written informed consent. The study was approved
by the University College London (UCL) ethics committee
and was conducted in accordance of the Declaration of
Helsinki. They were reimbursed £7.50/h and could win extra
money via completion of various tasks.
Assessments
Effort expenditure for rewards task (Fig. 1) (Treadway et al.
2012a)
This task tapped effort-related decision-making. Participants
made a series of decisions between two different effort op-
tions: a low-effort choice, in which a small amount of money
was available to be won (50p), and a high-effort choice, in
which a larger amount of money was available to be won
(80p, £1.00, £1.20, £1.40, £1.60, £1.80, £2.00). The low-
effort choice required 30 spacebar presses with the little finger
of the non-dominant hand in 7 s. The high-effort choice re-
quired 100 spacebar presses with the little finger of the non-
dominant hand in 21 s. Participants were not guaranteed to
win the money available if they completed the task; this was
determined probabilistically. On one third of the trials there
was a 12 % chance (low probability), on another third there
was a 50% chance (medium probability), and on another third
there was an 88 % (high probability) chance of winning the
money if they completed the required number of spacebar
presses in time. The probability level applied to both the
low-effort and high-effort choices.
The probability level and the amounts of money available
to be won were presented on screen to the participant (see
Fig. 1). Participants had 8 s to make their choice; if they did
not make a choice in that time, the computer randomly select-
ed one. Following a 0.5 s fixation cross and the spacebar-
pressing stage, 2 s of feedback was given about whether the
participant had successfully completed the spacebar-pressing
in time, and if successful, 2 s of feedback was given about
whether money had been won or not. Participants completed
21 trials in total, and the trial order was randomized.
Participants kept the amounts of money won on two trials;
these were randomly selected at the end of the task.
Important predictor variables in this task are probability
(chance of winning on each trial if the trial is completed),
magnitude (the amount of money available on the high-
effort choice) and expected value (the multiplication of prob-
ability and magnitude). Furthermore, previous research has
suggested that both earlier trials and male gender have been
associated with a greater likelihood of making a high-effort
choice (Treadway et al. 2009).
Trials were considered ‘incomplete’ if the participant did
not finish the button pressing in the allocated time.
1 As 17 is not divisible by 3, the Latin square was not completed with
equal numbers of participants in each treatment order.
Fig. 1 Diagrammatic representation of a single trial from the EEfRT. (1)
A fixation cross is shown for 0.5 s; (2) A choice is made between a low-
effort (i.e. easy) option and a high-effort (i.e. hard) option. The amount of
money available to be won for both the low-effort option and the high-
effort option is shown. The probability of winning the money if the
subsequent button-pressing is completed is shown (this is the same for
both options); (3) A fixation cross is shown for 0.5 s; (4) Button-pressing
is completed for 7 s, or until 30 presses are completed (low-effort option)
or 21 s, or until 100 presses are completed (high-effort option); (5)
Feedback is given about whether the button-pressing was completed in
time; (6) Feedback is given about whether money has been won and, if so,
how much
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Participants were excluded from the analysis if they failed to
complete ten or more trials on any one session. This was
because we wished to exclude participants who did not carry
out the task properly. The main outcome variable of the task
was, on each trial, whether the participant made a low-effort or
a high-effort choice.
It is possible that the speed at which a participant tapped
affected choice behaviour. Hence, before the actual task, they
were asked to press as fast as they could with their little finger
in order to complete 30 and 100 presses; the time taken to
make that number of presses (baseline button-pressing time)
was recorded.
It is important to note that the EEfRT used here (as de-
scribed above) was slightly different to the original EEfRT
(Treadway et al. 2009) in a number of ways, the original
version: (1) had more trials; (2) finished after a set amount
of time, not a set amount of trials; (3) used the dominant index
finger for the easy option; (4) had a continuous variation in
money available to be won; and (5) gave participants 5 s to
make their decision.
Drug history
Lifetime use was recorded as ‘yes’ or ‘no’. Current use (≥once
per month) was recorded as ‘yes’ or ‘no’. We asked those who
currently used how frequently (days/month) and how much
(amount/session) they used.
Beck depression inventory (Beck et al. 1996)
This scale of depression severity consisted of 21 items that
were rated for their frequency between 0 and 3 in the last
week. Higher scores reflected greater depression severity.
Temporal experiences of pleasure scale (Gard et al. 2006)
This trait anhedonia scale consists of 18 items that are rated
between 1 (very false for me) and 6 (very true for me). Two
subscale scores are produced, namely anticipatory anhedonia
and consummatory anhedonia. Higher scores reflect a greater
ability to experience pleasure.
Snaith Hamilton pleasure scale (Snaith et al. 1995)
This state scale consists of 14 items that are rated between 0
(definitely agree) and 3 (definitely disagree), in terms of how a
participant felt ‘right now’ (Powell et al. 2002). Higher scores
reflect greater anhedonia.
Severity of dependence scale (Gossop et al. 1995)
This standard scale of drug dependence consists of five items
that are rated between 0 and 4 in terms of frequency or diffi-
culty with higher scores reflecting greater dependence
severity.
‘Stoned’ ratings
Participants gave ratings for stoned, right now from 0 (not at
all) to 10 (extremely).
Drug administration
A Volcano Medic Vaporizer (Storz and Bickel, Tuttlingen,
Germany) was used to vaporize Bedrocan cannabis
(Veendan, the Netherlands). Across three occasions, we aimed
to administer 8 mg THC (Cann-CBD), 8 mg THC + 10 mg
CBD (Cann + CBD) and placebo (see Table 1). The amounts
of THC and CBD that we aimed to administer were based
broadly on previous THC/CBD vaporizer experiments
(Bossong et al. 2009; Hindocha et al. 2015a) and Bedrocan
product potencies (Brunt et al. 2014). This amount of THC is
approximately equal to that which would be found in one
quarter of a cannabis user’s joint, assuming that the cannabis
has 10 % THC (Freeman et al. 2014). Furthermore, cannabis
resin in the UK has approximately equal levels of THC and
CBD (Hardwick and King 2008), which is similar to the ratio
in the Cann + CBD in this study. Drugs were stored at −20 °C
in foil-sealed pouches, then at ambient temperature prior to
administration and then used within 6 months of purchase.
Each dose was vaporized in two sequentially administered
balloons to minimize residual cannabinoids. Participants were
provided with video training at screening and inhaled at their
Table 1 Target doses of THC and CBD for Cann-CBD, Cann + CBD
and placebo, and the weights of each cannabis type used to achieve them.
THC dose and total weight were matched across sessions by adjusting the
quantity of three cannabis varieties as shown below. All three cannabis
types contained terpenoids, creating the distinctive smell of cannabis
Cann-CBD Cann + CBD Placebo
Target dose 8 mg THC 8 mg THC + 10 mg CBD N/A
Total weight 133.4 mg 133.4 mg 133.4 mg
‘Bedrobinol’ (12 % THC, <1 % CBD) 66.7 mg N/A N/A
‘Bediol’ (6 % THC, 7.5 % CBD) N/A 133.4 mg N/A
Placebo (derived from ‘Bedrocan’; <0.3 % THC, <1 % CBD) 66.7 mg N/A 133.4 mg
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own pace (each inhalation held for 8 s) until the balloon was
empty. To maintain steady drug levels over time, participants
received a 50 % top-up dose approximately 90 min later.
Procedure
Following telephone screening, participants attended a screen-
ing visit consisting of eligibility assessment, task training,
drug history and trait questionnaires. Subsequently, they com-
pleted three testing sessions, on which they received Cann-
CBD, Cann + CBD or placebo separated by a washout period
of ≥7 days. Participants were asked to abstain from alcohol
and any illicit drugs for ≥24 h before each testing session.
Testing sessions began with a urine sample to screen for
pregnancy and to verify their recent self-reported drug use,
assessed by 7 day Timeline Followback (Sobell and Sobell
1992). After drug administration, participants underwent
MRI scanning for 1 h (data from the MRI section of the ex-
periment will be reported elsewhere). Next, they received their
top-up drug administration (approximately 90 min after the
first) and began an approximately 90-min long battery of be-
havioural tasks. Participants completed ratings of stoned at
five time points: (1) immediately before first drug administra-
tion (time ≈ 0 min), (2) immediately after first drug adminis-
tration (time ≈ 5 min), (3) immediately before second drug
administration (time ≈ 90 min), (4) immediately after second
drug administration (time ≈ 95 min) and (5) end of the session
(time ≈ 180 min).
Statistical analyses
All analyses were carried out using IBM Statistical Package
for Social Sciences (IBM SPSS version 22).
Stoned ratings were analysed using repeated measures
ANOVA with two within-subject factors: drug (placebo,
Cann-CBD, Cann + CBD) and time (1, 2, 3, 4, 5).
Interactions were explored with Bonferroni corrected t tests.
A repeated measures ANOVAwith a within-subject factor of
drug was used to analyse Snaith Hamilton pleasure scale
(SHAPS) scores.
Generalized estimating equation (GEE) models were used
to analyse the likelihood of participants making a high-effort
choice. GEE models allow the outcome variable to be non-
normally distributed with correlated residuals, which is a bi-
nary outcome in this case. GEE models allow parameters that
vary on a trial-by-trial basis to be incorporated and they deal
with missing data without excluding all of a participant’s data.
Furthermore, these characteristic mean GEE models have
more power to detect effects than general linear model ap-
proaches. The outcome measure was choice (high effort or
low effort), modelled using a binary logistic distribution. We
used an unstructured working correlation matrix.
Using the same approach as Treadway et al. (2009), we
tested the effect of drug condition, and its interaction with task
parameters on effort-related decision-making across four
models. Each model included the standard predictors accord-
ing to Treadway et al. (2009) (magnitude, probability, expect-
ed value, trial number, gender) and drug, with these additional
predictors: no others (model 1), drug × magnitude (model 2),
drug × probability (model 3) and drug × expected value (mod-
el 4). The categories of each factor were coded as follows:
drug placebo = 0, Cann-CBD = 1 and Cann + CBD = 2;
gender male = 0 and female = 1. Magnitude, probability, ex-
pected value and trial number were modelled as continuous
predictors.
Results
Demographics (Table 1 supplementary materials)2
Participants were aged 26.18 (SD = 7.13) years. On average,
they smoked cannabis 8.06 (5.48) days per month, took 25.88
(33.73) days to smoke an 8 ounce (3.5 g) of cannabis and
scored 1.13 (1.26) on the cannabis severity of dependence
scale (SDS).
Drugs in urine
During the placebo session, THC was detected in eight and
MDMA in one participants’ urine. During the Cann + CBD
session, THC was detected in nine and PCP in one partici-
pants’ urine. During the Cann-CBD session, THC was detect-
ed in eight participants’ urine. No participants reported using
any drugs within the last 24 h.
Stoned rating (Fig. 2)3
There was an interaction between time and drug
(F8,128 = 20.296, p < 0.001), main effects of time
(F4,64 = 82.443, p < 0.001) and drug (F2,32 = 56.154,
p < 0.001). Ratings of stoned were the same at time 1 for all
drug conditions. For every other time, both Cann-CBD and
Cann + CBD conditions had greater ratings of stoned com-
pared with placebo (all ps < 0.001) but did not differ from
other. Stoned ratings did not differ between time 2 and time
4 for Cann-CBD or Cann + CBD (both ps = 1.000), demon-
strating equivalent intoxication from the original dose and the
50 % top-up dose.
2 Data was missing for one participant for BDI, TEPS and drug history
3 One participant missed a rating at time 3 on the Cann + CBD session;
this was imputed from the group mean.
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Effort Expenditure for Rewards Task
Baseline button-pressing time There were no differences in
baseline button-pressing time between any of the sessions.
Generalized estimating equationmodels (Table 2)4Reward
magnitude and probability both positively and signifi-
cantly predicted making a high-effort choice in all
models (ps < 0.01). The effect of EV approached sig-
nificance in all models (ps < 0.1). As shown in model
1, Cann-CBD led to a lower likelihood of making a
high-effort choice than placebo (p = 0.042), but there
was no difference between Cann-CBD and Cann + CBD
(Fig. 3). Model 3 found an interaction between drug
and probability, such that Cann-CBD augmented the ef-
fect of probability on the likelihood of making a high-
effort choice relative to placebo (p = 0.029). Model 4
found an interaction between drug and EV, such that
Cann-CBD augmented the effect of EV on the likeli-
hood of making a high-effort choice relative to both
placebo (p = 0.014) and Cann + CBD (p = 0.006).
The drug by probability interaction in model 3 was
explored by carrying out GEE models within each level
of probability. At low probability, Cann-CBD led to a
lower likelihood of making high-effort choice than pla-
cebo (β = 0.188; SE = 0.0718; OR = 1.207; 95 % CI
1.049, 1.390). At medium and high probabilities, there
were no significant differences on the likelihood of
making a high-effort choice between Cann-CBD and
placebo conditions.
Given that expected value = probability × magnitude,
the drug by expected value interaction in model 4 was
explored by replacing expected value by probability ×
magnitude terms and then carrying out GEE models
within each level of probability (these models can be
found in Table 2 supplementary materials5). At low
probability, Cann-CBD led to a greater sensitivity to
magnitude than Cann + CBD (β = 0.412; SE = 0.156;
p = 0.008; OR = 1.510; 95 % CI 1.113, 2.048) and a
marginally greater sensitivity to magnitude than placebo
(β = 0.110; SE = 0.064; p = 0.086; OR = 1.117; 95 %
CI 0.985, 1.267). However, at medium and high proba-
bilities, there were no interactions between drug and
magnitude. Therefore, the increase in sensitivity to ex-
pected value following Cann-CBD administration rela-
tive to Cann + CBD and placebo, found in model 4,
can be attributed to an increase in sensitivity to magni-
tude changes at low probability following Cann-CBD, at
least compared to Cann + CBD.
Results concerning the time to complete a trial and the
number of completed trials within each drug condition are
provided in the supplementary materials.
Snaith Hamilton pleasure scale
There was no effect of drug (F2,32 = 0.248, p = 0.782).
Study 2
Methods
Participants and design
Twenty cannabis-dependent individuals were compared
with 20 controls, with eligibility criteria based on
Morgan et al. (2012). Inclusion criteria for the
cannabis-dependent participants were as follows: score
≥3 on the SDS for cannabis (indicative of dependence:
Swift et al. 1998); smoke high-potency cannabis
(‘skunk’) on 50 % or more of the occasions that they
smoke cannabis; and score ≤2 on the SDS for all other
drugs, except tobacco and alcohol. Participants in the
control group were selected to match the cannabis-
dependent group in terms of other (non-cannabis) drug
use and had to score ≤2 on the SDS for all drugs,
except tobacco and alcohol. Exclusion criteria for either
group were as follows: currently seeking treatment for a
mental health problem; current use of psychiatric medi-
cation; or diagnosis of alcohol dependence.
Participants were reimbursed £10/h. The study was ap-
proved by the UCL ethics committee, all participants provided
written informed consent and the study was conducted in ac-
cordance with the Declaration of Helsinki.
Assessments
The following measures were used as described in experiment
1: EEfRT, Beck depression inventory (BDI), temporal experi-
ences of pleasure scale (TEPS), drug history and cannabis
SDS.
Probabilistic Reward Task (Pizzagalli et al. 2005) (Fig. 4)
The task used abstract faces with two different lengths of
mouth as the stimuli. The short mouth was 8 mm and the long
mouth was 9 mm. The participant’s aim was to quickly deter-
mine whether the mouth was short or long. They sometimes
won money (5p) if they correctly determined whether the
mouth was long or short.
The task composed two blocks of 100 trials. The
trials were pseudo-randomized such that a maximum
4 We excluded one participant for failing to complete 13 and 14 trials on
two of his sessions, thus he clearly did not complete the task as instructed.
5 We thank an anonymous reviewer for this suggestion.
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of 3 long or short mouths appeared consecutively. At
the start of each trial, a fixation-cross was presented
for a jittered time (750, 800, 850, or 900 ms). A
mouthless face was then presented for 500 ms followed
by the appearance of the mouth in the face for 97 ms.
After the mouth disappeared, the mouthless face
remained on the screen for 1500 ms or until the partic-
ipant responded with the ‘v’ or ‘m’ key. The participant
pressed the ‘v’ key if they thought the mouth was short
and pressed the ‘m’ key if they thought the mouth was
long. Subsequently, feedback was provided for 1500 ms,
e.g. ‘Correct!!! You won 5p’ and then a blank screen
was shown for 2000 ms.
Critically, one of stimuli/mouths (the ‘rich’ stimulus)
was reinforced three times more frequently than the
other stimulus/mouth (the ‘lean’ stimulus). Each block
had 50 rich stimuli and 50 lean stimuli; 30 of the rich
stimuli had the opportunity for reinforcement, while 10
of the lean stimuli had the opportunity for reinforce-
ment. If a stimulus with the opportunity for reinforce-
ment was not correctly identified, the next stimulus of
that type (rich or lean) that was not going to be
reinforced became a stimulus with the opportunity for
reinforcement. This was to ensure that participants had
similar numbers of reinforced rich and lean stimuli (ide-
ally 30 and 10 respectively). Before the task began,
participants were told that only some of the correct re-
sponses would be reinforced but they were not told that
one of the stimuli was more likely to be reinforced than
the other. An equal number of participants did the
Probabilistic Reward Task (PRT) with the long mouth
as the rich stimulus and the short mouth as the rich
stimulus.
The differences between our task and the original PRT
(Pizzagalli et al. 2005) were that, on our task, (1) participants
won 5p on a successful trial, rather than 5 cents; (2) there were
200 trials split into two 100 trial blocks, rather than 300 trials
split into 3 blocks; and (3) the mouth lengths were 8 and
9 mm, rather than 11.5 and 13 mm.
Trials and participants were excluded based on stan-
dard exclusionary criteria (Alexis Whitton, personal
communication; Janes et al. 2015). Response bias
(RB), discriminability, accuracy and reaction time were
calculated as in previous papers.
Trials were excluded from analysis if the participant
responded with a reaction time (RT) <100 ms or
>1500 ms. Participants were excluded if, on either
block, they had >20 % excluded trials, received rein-
forcement on <25 rich stimuli, received reinforcement
on <6 lean stimuli, had <55 % accuracy for the rich
stimulus and had <55 % accuracy overall (Alexis
Whitton personal communication; Janes et al. 2015).
Response bias, which indexed a person’s bias towards the
more frequently reinforced stimulus, was calculated using the
following formula:
Response bias ¼ 1
2
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Fig. 2 Mean (SE) scores for
subjective ratings of ‘stoned’ and
at five time points in study 1.
Time 1 = immediately before first
drug administration (0 min), time
2 = immediately after first drug
administration (≈5 min), time
3 = immediately before second
drug administration (≈90 mins),
time 4 = immediately after second
drug administration (≈95 min),
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Fig. 3 Mean (SE) numbers of high-effort choices made during each drug
condition, collapsed across probability and magnitude, in study 1. There
were 21 trials on each condition, so there were a maximum of 21 high-
effort choices to be made. Error bars show standard error
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Discriminability, which indexed a person’s ability to differ-
entiate the stimuli, was calculated using the following
formula:
Discriminability ¼ 1
2
*log
Rich correct*Lean correct
Rich incorrect*Lean incorrect
Rich_correct refers to the number of rich stimuli that
was correctly identified. Lean_correct refers to the num-
ber of lean stimuli that was correctly identified.
Rich_incorrect refers to the number of rich stimuli that
was incorrectly identified. Lean_incorrect refers to the
number of lean stimui that was incorrectly identified.
Table 2 GEE models for EEfRT
from study 1 Beta SE p value Odds ratio 95 % CI OR
Model 1
Magnitude 0.114 0.0315 <0.001 1.188 1.054, 1.193
Probability 0.172 0.0352 <0.001 1.121 1.109, 1.272
Expected value 0.134 0.0786 0.089 1.143 0.980, 1.333
Trial number −0.008 0.0015 <0.001 0.992 0.989, 0.995
Gender 0.220 0.0720 0.002 1.246 1.082, 1.435
Placebo vs. Cann-CBD 0.050 0.0247 0.042 1.051 1.002, 1.103
Cann + CBD vs. Cann-CBD −0.001 0.0280 0.976 0.999 0.946, 1.056
Model 2
Magnitude 0.140 0.0405 0.001 1.151 1.063, 1.246
Probability 0.173 0.0353 <0.001 1.189 1.110, 1.274
Expected value 0.131 0.0786 0.095 1.140 0.978, 1.330
Trial number −0.008 0.0015 <0.001 0.992 0.989, 0.995
Gender 0.220 0.0721 0.002 1.246 1.082, 1.435
Placebo vs. Cann-CBD 0.097 0.054 0.073 1.102 0.991, 1.224
Cann + CBD vs. Cann-CBD 0.055 0.0590 0.347 1.057 0.942, 1.187
(Placebo vs. Cann-CBD) × magnitude −0.033 0.0375 0.385 0.968 0.899, 1.042
(Cann + CBD vs. Cann-CBD) × magnitude −0.039 0.0395 0.320 0.961 0.890, 1.039
Model 3
Magnitude 0.115 0.0313 <0.001 1.122 1.055, 1.193
Probability 0.206 0.0405 <0.001 1.229 1.135, 1.331
Expected value 0.131 0.0783 0.094 1.140 0.978, 1.329
Trial number −0.008 0.0015 <0.001 0.992 0.989, 0.995
Gender 0.219 0.0716 0.002 1.245 1.082, 1.433
Placebo vs. Cann-CBD 0.123 0.0342 <0.001 1.131 1.057, 1.209
Cann + CBD vs. Cann-CBD 0.044 0.0356 0.212 1.045 0.975, 1.121
(Placebo vs. Cann-CBD) × probability −0.060 0.0276 0.029 0.942 0.892, 0.994
(Cann + CBD vs. Cann-CBD) × probability −0.036 0.0199 0.073 0.965 0.928, 1.003
Model 4
Magnitude 0.117 0.0313 <0.001 1.124 1.057, 1.195
Probability 0.175 0.0352 <0.001 1.192 1.112, 1.277
Expected value 0.201 0.0793 0.011 1.223 1.047, 1.428
Trial number −0.008 0.0015 <0.001 0.993 0.990, 0.995
Gender 0.219 0.0717 0.002 1.245 1.082, 1.433
Placebo vs. Cann-CBD 0.149 0.0387 <0.001 1.161 1.076, 1.253
Cann + CBD vs. Cann-CBD 0.078 0.0388 0.045 1.081 1.002, 1.166
(Placebo vs. Cann-CBD) × EV −0.121 0.0494 0.014 0.886 0.804, 0.976
(Cann + CBD vs. Cann-CBD) × EV −0.093 0.0337 0.006 0.911 0.853, 0.973
The likelihood of making a high-effort choice was predicted from each of the variables shown in the tables. Beta
coefficients for each predictor term, standard errors, p values, odds ratios (ORs) and 95 % confidence intervals
(CI) for these ORs are shown. The most important terms are in bold
3544 Psychopharmacology (2016) 233:3537–3552
The task therefore produces one main outcome, response
bias, and three other important outcomes: discriminability,
accuracy and reaction time.
Spot-the-word (Baddeley et al. 1993)
This test, which correlates highly with premorbid verbal intel-
ligence, consists of pairs of items: one’s a word and one’s a
non-word. Participants decided which they thought was a real
word.
Procedure
Following telephone screening, participants completed one 2-
h testing session. First, participants answered demographic
and drug use questions, stated which drugs they had taken
over the last 48 h and completed the spot-the-word test.
Subsequently, they completed the EEfRT, the BDI, the
TEPS and the PRT and provided a urine sample. Participants
also completed three other cognitive tasks and questionnaires
concerning psychosis-like symptoms, which will be reported
elsewhere.
Statistical analyses
All analyses were carried out using IBM Statistical
Package for Social Sciences (IBM SPSS version 22).
Where appropriate, errors were checked for normality,
unbiasedness and homoscedasticity using inspection of
histograms and Levene’s test. Non-parametric tests were
used when data did not meet the above assumptions,
and a suitable test was available.
Analysis of the EEfRTwas conducted in the sameway as in
study 1.We tested whether group and its interactions with task
parameters affected the likelihood of making a high-effort
choice across four models. Each model included the standard
predictors (see above) and group, with the additional predic-
tors: no others (model 1), group × magnitude (model 2), group
× probability (model 3) and group × expected value (model 4).
Each model also included BDI, average number of cigarettes/
day and baseline button-pressing time because of group dif-
ferences on these variables. The models were also run without
these three extra predictors to see if it affected the pattern of
results.
For the PRT, RB and discriminability were analysed
with mixed ANOVAs with a between-subject factor of
group (controls, cannabis) and within-subject factors of
block (1, 2). Accuracy and RTs were analysed in the same
way but with an extra within-subject factor of stimulus
(rich, lean). ANCOVAs were used to investigate whether
inclusion of BDI and average number of cigarettes/day af-
fected results.
Correlations were computed for composite RB (averaged
across blocks 1 and 2) and ΔRB (change between blocks 1 and
2) with BDI, average number of cigarettes/day (which in-
cludes those who do not smoke and those who do not smoke
every day) and cannabis-SDS in each group separately.
Results
Demographics (Table 3 supplementary materials)
The groups did not differ in gender, age, highest level
of education achieved or any measure of illicit drug use.
Fig. 4 Diagrammatic
representation of the Probabilistic
Reward Task (Pizzagalli et al.
2005). (1) A fixation cross is
shown for a jittered time (750 ms,
800 ms, 850 ms, or 900 ms), (2) a
mouthless face is shown for
500 ms; (3) the mouth is added to
the face for 97 ms; (4) the
mouthless face is shown for
1500 ms or until the participant
responds, stating they thought it is
the long or short mouth; (5)
feedback is given for 1500ms; (6)
a blank screen is shown for
2000 ms
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However, compared with the controls, the cannabis
g roup , on average , had a h igher BDI score6
(t38 = 2.932, p = 0.006), a lower spot-the-word score
(t38 = 2.585, p = 0.014) and smoked more cigarettes/
day (t38 = 4.411, p < 0.001).
All but two of the cannabis group smoked cannabis
every day; one participant smoked approximately
22 days per month and another smoked approximately
12 days per month. The cannabis group smoked an
average of 1.49 g (1.41) per session and had an average
cannabis SDS score of 7.30 (3.39). Eight controls
smoked cannabis at least once per month, with an av-
erage of 3.94 days (1.78) per month and an average of
0.31 g (0.28) per session. None of the controls scored
>0 on the cannabis SDS.
Recent drug use
No participants reported using cannabis, alcohol or any other
illicit drug within 12 h of testing.
In the control group, there were positive urine tests for
THC (n = 4), benzodiazepines (n = 2), buprenorphine
(n = 2), cocaine (n = 1), PCP (n = 1) and opioids (n = 1).7 In
the cannabis group, there were positive urine tests for THC
(n = 19), cocaine (n = 2) and opioids (n = 2).
Effort Expenditure for Rewards Task
Baseline button-pressing time The controls were faster than
the cannabis-dependent participants to complete 30 and 100
button presses (t37 = 3.113, p = 0.004). As a result, baseline
button-pressing time was included in the GEE models.
Generalized estimating equation models (Table 4
supplementary materials).8 Reward magnitude and prob-
ability positively predicted making a high-effort choice
in all models (ps < 0.05), and expected value did so in
all but one of the models (ps < 0.05). Participants were
less likely to make a high-effort choice as the task went
on, as demonstrated by the negative effect of trial num-
ber (ps < 0.001). However, there was no overall differ-
ence in motivation between the groups and no interac-
tions between group and magnitude, probability or ex-
pected value. The pattern of these results did not change
when we removed baseline button-pressing, BDI and
average number of cigarettes/day from the models.
Probabilistic Reward Task
Response bias (Fig. 5)9Repeatedmeasures ANOVA revealed
a trend interaction between group and block (F1,27 = 3.579,
p = 0.069), a main effect of group, indicating lower RB in the
cannabis group (F1,27 = 8.531, p = 0.007), and a trend effect of
block, reflecting increased RB from blocks 1 to 2
(F1,27 = 2.978, p = 0.096).
Exploration of the trend group by block interaction showed
that RB increased from blocks 1 to 2 in controls (t14 = 2.604,
p = 0.015) but not cannabis users (t13 = 0.109, p = 0.909).
Furthermore, RB was significantly greater in controls than
cannabis users during block 2 (t25 = 3.00, p = 0.005) but only
marginally so in block 1 (t25 = 1.831, p = 0.082).
All of these effects were lost when BDI and average num-
ber of cigs/day were included as covariates. There was a trend
main effect of BDI (F1,25 = 3.464, p = 0.075) and no effect of
cigs/day.
The pattern of results did not change if all of the partici-
pants were included in the analysis.
Discriminability
There was a trend towards an effect of block, with greater
discriminability in block 2 compared with block 1
(F1,27 = 3.605, p = 0.068), no effect of group nor an interaction
between the two. The trend effect of block was lost when BDI
and average number of cigs/day were included as covariates.
Accuracy
There was an interaction between group and stimulus
(F1,27 = 8.723, p = 0.006) and a main effect of stimulus, with
greater accuracy for the rich stimulus (F1,27 = 28.109,
p < 0.001). No other effects or interactions were significant.
Exploration of the interaction showed that the controls had
greater accuracy for the rich stimulus compared with the lean
stimulus (t14 = 5.941, p < 0.001) while the cannabis group did
not. The main effect of stimulus remained after including the
covariates, but the interaction between group and stimulus
was lost.
Reaction time
There was a main effect of stimulus, with a faster response to
the rich stimulus compared with the lean stimulus
(F1,27 = 7.684 p = 0.010). No other effects or interactions were
significant. This effect was unchanged when including the
covariates.6 One control’s BDI score was missing so it was imputed from the group
mean
7 One control’s urine test results were missing
8 One cannabis-dependent participant was excluded because they failed
to complete 16 trials.
9 Eleven out of 40 participants were excluded due to not meeting task
criteria, 5 were drug-using controls and 6 were cannabis-dependent
participants.
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Correlations
Within each group separately, none of the correlations exam-
ined reached significance.
Discussion
Historically, cannabis use has been linked to amotivation
(McGlothlin and West 1968), and cannabis dependence is
theoretically associated with non-drug reward processing def-
icits (Goldstein and Volkow 2011), although empirical evi-
dence for these claims is lacking. To the authors’ knowledge,
this report is the first to examine the acute effects of different
cannabinoids on effort-related decision-making and to inves-
tigate associations between cannabis dependence and effort-
related decision-making and reward learning.
In study 1, acute administration of cannabis without CBD
(Cann-CBD) reduced the overall likelihood of making high-
effort choices (i.e. motivation) for monetary reward compared
with placebo. Contrary to our hypothesis, this effect was not,
overall, attenuated by cannabis with CBD (Cann + CBD).
However, Cann-CBD increased sensitivity to expected value
of the monetary outcomes, relative to both placebo
(OR = 1.129) and Cann + CBD (OR = 1.092); this was due
tomagnitude having a greater effect on behaviour in the Cann-
CBD condition at low probability. These data therefore sug-
gest that acute cannabis administration can lead to transient
amotivation and they provide some evidence that CBD par-
tially moderates the effects of THC onmotivation, via altering
the way THC interacts with expected value. In study 2, no
relationship between cannabis dependence and effort-related
decision-making emerged. However, cannabis-dependent par-
ticipants had overall weaker reward learning than the controls,
and the cannabis-dependent participants also failed to improve
their response bias between blocks. Due to other group differ-
ences and the nature of the study, it is hard to conclude
whether these effects were driven by cannabis dependence
or confounding variables, such as depression.
Acute cannabis and motivation
Despite enduring beliefs that cannabis acutely reduces moti-
vation, we are aware of only one controlled study which used
a work-for-reward design (Cherek et al. 2002), and they had a
sample of five participants. Some older work had suggested
null (Mello and Mendelson 1985; Mendelson et al. 1976) or
pro-motivational (Foltin et al. 1990) effects of acute cannabis;
however, these studies were not well controlled or did not
provide a clear reward respectively. Here, the results provide
evidence to support this hypothesis using a task that has pre-
viously demonstrated sensitivity to anhedonia, major depres-
sive disorder and dopaminergic function ( Treadway et al.
2009, 2012a, b; Wardle et al. 2011). In the first model, place-
bo, relative to Cann-CBD, was a significant, positive predictor
of the likelihood of making a high-effort choice. Hence, the
administration of Cann-CBD reduced motivation for mone-
tary reward, and this supports a transient amotivational effect.
It is difficult to speculate on the pharmacology underlying this
effect. THC may boost dopamine release (Bossong et al.
2009), which would be expected to enhance motivation, but
we found the opposite. The endocannabinoid system’s role in
motivation must be more clearly elucidated before attempting
to explain in detail THC’s amotivational effects, but this result
at least suggests that functioning of CB1 receptors is impor-
tant in effort-related decision-making.
Although CBD has been shown to shield individuals
against some of the negative effects of THC (Englund et al.
2013; Hindocha et al. 2015a; Morgan et al. 2010a), the overall
difference between Cann-CBD and Cann + CBD was null in
the first model. There is thus no evidence that cannabidiol
reduced the overall amotivational effects of THC. It may be
the case that a higher dose of cannabidiol or a different time of
administration relative to THC is needed to produce a stronger
pro-motivational effect.
Fig. 5 Means (SE) for response
bias on the PRT for the control
participants (control) and the
cannabis-dependent (cannabis)
participants, on blocks 1 and 2, in
study 2. Out of 40 participants, 11
were excluded; 5 were from the
drug-using control group and 6
were from the cannabis dependent
group. Error bars show standard
error
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However, Cann-CBD influenced the effects of expected
value on effort-related decision-making differently to Cann
+ CBD. Expected value refers to the multiplication of the
outcome value with the probability of receiving the outcome,
so it represents how good an option is and how much it is
worth. According to model 4, expected value increased the
likelihood of making a high-effort choice more following ad-
ministration of Cann-CBD than placebo and Cann + CBD.
This implies that CBD affected the way people made deci-
sions about different effortful outcomes. Further exploration
showed that these drug by expected value interactions were at
least partially due to Cann-CBD, significantly and marginally
increasing sensitivity to magnitude on low probability trials
relative to Cann + CBD and placebo respectively. In other
words, at low probability, magnitude had a larger effect on
behaviour following Cann-CBD than Cann + CBD and, to
some extent, placebo. These results could suggest that the
presence of CBD attenuated THC’s effects on the processing
of expected value, such that Cann + CBD was more similar to
placebo than Cann-CBD, in this regard. Alternatively, one
could conclude that the presence of CBD made it less like
placebo: Cann-CBD augmented the effect of expected value
more than Cann + CBD and placebo, so this means that as
expected value increased, Cann-CBD somewhat recovered
from its amotivational effects, while Cann + CBD did not.
Therefore, CBD’s role in effort-related decision-making is
slightly ambiguous. Replications of this study are needed be-
fore any conclusive remarks about CBD’s motivational qual-
ities are made.
Importantly, becoming stoned is a major motivator for can-
nabis use and it is noteworthy that CBD did not compromise
this desired effect of THC, consistent with previous findings
(Haney et al. 2015; Hindocha et al. 2015a). The lack of CBD’s
effect on stoned ratings may be important in harm reduction
messages if users wish to maintain the degree to which they
feel subjective effects, while potentially reducing some of the
harmful consequences of THC (Curran et al. 2016).
Cannabis dependence and reward processing
impairments
No association emerged between cannabis dependence and
effort-related decision-making. The results are concordant
with previous survey-based research which have failed to find
a relationship between long-term cannabis use and self-
reported motivation (Barnwell et al. 2006; Musty and
Kaback 1995). Thus, these results imply that cannabis acutely
but not chronically alters effort-related decision-making.
However, given the cross-sectional nature of the study, the
results should be interpreted cautiously. A large, longitudinal
study that records frequency of cannabis use, type of cannabis
used and different aspects of motivation is needed to more
thoroughly address the question of how chronic use might
relate to amotivation.
Similar to the associations with depression (Pizzagalli et al.
2008) and nicotine withdrawal (Pergadia et al. 2014), we dem-
onstrated that cannabis dependence (with >12 h of abstinence)
was associated with reduced reward learning compared with
non-dependent, drug-using controls. Not only did the
cannabis-dependent individuals have an overall reduced re-
sponse bias, but they also did not improve their response bias
between blocks, as is usually seen in healthy controls
(Pizzagalli et al. 2005), although the group by block interac-
tion was only a trend.
Drug addiction has been associated with deficits in non-
drug reward processing (Goldstein and Volkow 2002;
Lubman et al. 2009) and anhedonia (Garfield et al. 2014;
Hatzigiakoumis et al. 2011; Leventhal et al. 2008). Given
cannabis’s putative effects on reward circuitry (Bloomfield
et al. 2014a; Maldonado et al. 2006) and the depressive effects
of cannabis withdrawal (Budney and Hughes 2006), our find-
ing concerning reduced reward learning was expected.
Whether this reward deficiency was a consequence of chronic
cannabis, a predisposing factor for cannabis use, other factors
or a combination of these remain to be seen and will require
longitudinal studies. Whatever the causal relationships, a re-
duced capacity to direct behaviour towards more reinforced
stimuli is an important finding as it may contribute to reduced
subjective wellbeing and could negatively impact treatment
success, as seen in depression (Vrieze et al. 2013).
Although the groups were very similar in terms of
other illicit drug use, age, gender and educational
achievement, they did differ significantly in depression
levels and tobacco use. This is not surprising, given that
depression and tobacco use are positively associated
with cannabis dependence (Hindocha et al. 2015b). We
found that when these factors were included as covari-
ates, the effects of group and block were lost. Given
this result and the strong relationship between depres-
sion and reward responsiveness on the PRT (Pizzagalli
et al. 2005, 2008), as well as emerging evidence that
tobacco use and nicotine withdrawal affect task behav-
iour (Janes et al. 2015; Liverant et al. 2014; Pergadia
et al. 2014), drawing any conclusions about specific
relationships between cannabis use, tobacco use, depres-
sion and reward learning is difficult. However, just be-
cause the effect of group was lost when depression and
cigarette smoking were included as covariates, this does
not mean that cannabis dependence is not associated
with reduced reward learning. As a relatively large
amount of variance was shared between group and to-
bacco use (approximately 30 %) and depression (ap-
proximately 20 %), covarying for these variables is
not statistically optimal and may be considered inappro-
priate (Miller and Chapman 2001). Future case-control
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studies should therefore aim to match groups on depres-
sion and cigarette smoking.
It is also important to note that we did not include a healthy,
non-drug-using control group in this study. Cannabis-
dependent individuals may well have impaired effort-related
decision-making and reward learning relative to this alterna-
tive group. Indeed, the drug-using controls in study 2 may
even have some reward-processing deficits relative to healthy
controls. However, our choice of control group provided the
most conservative test for reward-processing deficits attribut-
able to chronic cannabis use.
Strengths and limitations
Study 1 was a placebo-controlled, double-blind experiment
and so provides strong evidence for cannabis causing transient
amotivation. To the authors’ knowledge, this is the first time
this has been shown in an adequately powered study (they are
consistent with a previous study (Cherek et al. 2002) with a
sample size of five). Furthermore, the investigation of CBD
was highly novel. We found preliminary evidence that it can
moderate the effects of THC on effort-related decision-mak-
ing. The drug administration protocol was effective as stoned
ratings were similar immediately after the first and second
doses. Although cannabis-dependent participants were more
depressed and smoked more cigarettes than drug-using con-
trols in study 2, they were well matched on all other demo-
graphic variables, including other drug use, which is a key
strength.
One important limitation of both studies was that there
were positive drug urine test results for various participants,
and residual drug effects could have affected task perfor-
mance. Furthermore, the criteria for inclusion in the cannabis
dependent group could have been improved by carrying out
interviews to assess DSM cannabis dependence/use disorder.
Although all cannabis-dependent participants smoked skunk
on ≥50 % times they smoked cannabis, we did not actually
assess preference of cannabis type in the cannabis-dependent
group and so we may have missed out on reward-processing
differences between skunk-preferring and hash-preferring
participants.
While these two studies have addressed the acute effects of
cannabis on and association of cannabis dependence with re-
ward processing, we only employed one type of reward.Money,
as a secondary reward, activates somewhat different brain re-
gions compared with primary rewards (Sescousse et al. 2010)
and may also be considered a way of buying drugs, rather than
being seen as a reward in itself. Future studies should investigate
reward processing of a variety of rewards, including cannabis
itself, so that comparisons between drug and non-drug reward
processing can be made (Lawn et al. 2015). Moreover, although
urinalysis was conducted in both experiments, we were not able
to relate task performance to quantitative indices of cannabinoid
metabolites, which could have improved our ability to infer
acute and chronic effects of THC and CBD (Morgan et al.
2012). Finally, study 2 could obviously have been improved if
depression and cigarette smokingwere not different between the
groups.
Conclusions
In conclusion, cannabis without CBD led to an overall reduc-
tion in motivation as evidenced by a lower likelihood of mak-
ing a high-effort choice to earn monetary reward. Cannabis
with CBD did not appear to reduce this effect but did moderate
THC’s effects on expected value to some extent. Cannabis
dependence was associated with preserved motivation and
impaired reward learning. However, given the observational
nature of the data and the confounding group differences, it is
difficult to ascertain what caused the impaired reward learn-
ing. In summary, these results support a transient
amotivational syndrome caused by acute cannabis administra-
tion but do not support a chronic amotivational syndrome
associated with cannabis dependence. Future research should
employ large, longitudinal designs to better probe reward pro-
cessing impairments in long-term cannabis users.
Compliance with ethical standards The study was approved by the
UCL ethics committee, all participants provided written informed consent
and the study was conducted in accordance with the Declaration of
Helsinki.
Funding Study 1 was funded by Drug Science. The cannabis used in
study 1 was bought from Bedrocan (Veendam, thew Netherlands). Study
2 was funded by WL’s PhD grant from the BBSRC and University
College London.
Conflicts of interest HVC is a member of the UK MRC boards and
Drug Science.
DJN is an advisor to the British National Formulary, MRC, GMC,
Department of Health; President of European Brain Council; Past
President of British Neuroscience Association and European College of
Neuropsychopharmacology, Chair of Drug Science (UK); Member of
International Centre for Science in Drug Policy; Advisor to Swedish
government on drug, alcohol, and tobacco research; editor of the
Journal of Psychopharmacology; Member of Advisory Boards of
Lundbeck, MSD, Nalpharm, Orexigen, Shire, MSD; has received speak-
ing honoraria (in addition to above) from BMS/Otsuka, GSK, Lilly,
Janssen, Servier, AZ, and Pfizer; is a member of the Lundbeck
International Neuroscience Foundation; has received grants or clinical
trial payments from P1vital, MRC, NHS, Lundbeck, RB; has share op-
tions in P1vital; has been an expert witness in a number of legal cases
relating to psychotropic drugs; and has edited/written 27 books, some
purchased by pharma companies.
CJAM has consulted for Janssen and GlaxoSmithKline and received
compensation.
MBW is employed by Imanova Ltd., a private company that performs
contract research work for the pharmaceutical industry.
The authors declare that they have no conflict of interest.
Psychopharmacology (2016) 233:3537–3552 3549
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
References
Albrecht DS, Skosnik PD, Vollmer JM, Brumbaugh MS, Perry KM,
Mock BH, Zheng Q-H, Federici LA, Patton EA, Herring CM
(2013) Striatal D2/D3 receptor availability is inversely correlated
with cannabis consumption in chronic marijuana users. Drug
Alcohol Depend 128:52–57
Baddeley A, Emslie H, Nimmo-Smith I (1993) The spot-the-word test: a
robust estimate of verbal intelligence based on lexical decision. Br J
Clin Psychol 32:55–65
Barnwell SS, EarleywineM,Wilcox R (2006) Cannabis, motivation, and life
satisfaction in an internet sample. Subst Abuse Treat Prev Policy 1:2
Beck AT, Steer RA, Ball R, Ranieri WF (1996) Comparison of Beck
Depression Inventories-IA and-II in psychiatric outpatients. J Pers
Assess 67:588–597
Berridge KC, Robinson TE (1998) What is the role of dopamine in re-
ward: hedonic impact, reward learning, or incentive salience? Brain
Res Rev 28:309–369
Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R,
Borgwardt S, Winton-Brown T, Nosarti C, MO’Carroll C, Seal M,
Allen P (2010) Opposite effects of Δ-9-tetrahydrocannabinol and
cannabidiol on human brain function and psychopathology.
Neuropsychopharmacology 35:764–774
Bloomfield MA, Morgan CJ, Egerton A, Kapur S, Curran HV, Howes OD
(2014a) Dopaminergic function in cannabis users and its relationship
to cannabis-induced psychotic symptoms. Biol Psychiatry 75:470–478
Bloomfield MA, Morgan CJ, Kapur S, Curran HV, Howes OD (2014b) The
link between dopamine function and apathy in cannabis users: an [18F]-
DOPA PET imaging study. Psychopharmacology 231:2251–2259
Bossong MG, van Berckel BN, Boellaard R, Zuurman L, Schuit RC,
Windhorst AD, van Gerven JM, Ramsey NF, Lammertsma AA,
Kahn RS (2009)Δ9-Tetrahydrocannabinol induces dopamine release
in the human striatum. Neuropsychopharmacology 34:759–766
BossongMG,MehtaMA, vanBerckel BN,HowesOD,KahnRS, Stokes PR
(2015) Further human evidence for striatal dopamine release in-
duced by administration ofΔ9-tetrahydrocannabinol (THC): selec-
tivity to limbic striatum. Psychopharmacology 232:2723–2729
Bovasso GB (2001) Cannabis abuse as a risk factor for depressive symp-
toms. Am J Psychiatr 158:2033–2037
Brunt TM, van Genugten M, Höner-Snoeken K, van de Velde MJ,
Niesink RJ (2014) Therapeutic satisfaction and subjective effects
of different strains of pharmaceutical-grade cannabis. J Clin
Psychopharmacol 34:344–349
Budney AJ, Hughes JR (2006) The cannabis withdrawal syndrome. Curr
Opin Psychiatry 19:233–238
Cherek DR, Lane SD, Dougherty DM (2002) Possible amotivational
effects following marijuana smoking under laboratory conditions.
Exp Clin Psychopharmacol 10:26–38
Curran HV, Freeman TP,Mokrysz C, Lewis DA,Morgan CJ, Parsons LH
(2016) Keep off the grass? Cannabis, cognition and addiction. Nat
Rev Neurosci 17:293–306
CurranVH,Brignell C, Fletcher S,Middleton P, Henry J (2002)Cognitive and
subjective dose-response effects of acute oral Δ9-tetrahydrocannabinol
(THC) in infrequent cannabis users. Psychopharmacology 164:61–70
D’Souza DC, Cortes-Briones JA, RanganathanM, Thurnauer H, Creatura
G, Surti T, Planeta B, Neumeister A, Pittman B, Normandin M
(2015) Rapid changes in CB1 receptor availability in cannabis de-
pendent males after abstinence from cannabis. Biological
Psychiatry: Cognitive Neuroscience and Neuroimaging 1:60–67
Englund A, Morrison PD, Nottage J, Hague D, Kane F, Bonaccorso S,
Stone JM, Reichenberg A, Brenneisen R, Holt D (2013) Cannabidiol
inhibits THC-elicited paranoid symptoms and hippocampal-dependent
memory impairment. J Psychopharmacol 27:19–27
Flagel SB, Clark JJ, Robinson TE,Mayo L, Czuj A,Willuhn I, Akers CA,
Clinton SM, Phillips PE, Akil H (2011) A selective role for dopa-
mine in stimulus-reward learning. Nature 469:53–57
Foltin RW, Fischman MW, Brady JV, Bernstein DJ, Capriotti RM, Nellis
MJ, Kelly TH (1990) Motivational effects of smoked marijuana:
behavioral contingencies and low-probability activities. J Exp
Anal Behav 53:5
Freeman, Winstock A (2015) Examining the profile of high-potency can-
nabis and its association with severity of cannabis dependence.
Psychol Med 45:3181–3189
Freeman TP, Morgan CJ, Hindocha C, Schafer G, Das RK, Curran HV
(2014) Just say ‘know’: how do cannabinoid concentrations influ-
ence users’ estimates of cannabis potency and the amount they roll
in joints? Addiction 109:1686–1694
Gard DE, Gard MG, Kring AM, John OP (2006) Anticipatory and con-
summatory components of the experience of pleasure: a scale devel-
opment study. J Res Pers 40:1086–1102
Garfield JB, Lubman DI, Yücel M (2014) Anhedonia in substance use
disorders: a systematic review of its nature, course and clinical cor-
relates. Aust N Z J Psychiatry 48:36–51
Goldstein RZ, Volkow ND (2002) Drug addiction and its underlying
neurobiological basis: neuroimaging evidence for the involvement
of the frontal cortex. Am J Psychiatr 159:1642–1652
Goldstein RZ, Volkow ND (2011) Dysfunction of the prefrontal cortex in
addiction: neuroimaging findings and clinical implications. Nat Rev
Neurosci 12:652–669
Gossop M, Darke S, Griffiths P, Hando J, Powis B, Hall W, Strang J
(1995) The severity of dependence scale (SDS): psychometric prop-
erties of the SDS in English and Australian samples of heroin, co-
caine and amphetamine users. Addiction 90:607–614
Haney M, Malcolm R, Babalonis S, Nuzzo P, Cooper Z, Bedi G, Gray K,
McRae-Clark A, Lofwall M, Sparenborg S (2015) Oral cannabidiol
does not alter the subjective, reinforcing or cardiovascular effects of
smoked cannabis. Neuropsychopharmacology
Hardwick S, King LA (2008) Home Office cannabis potency study 2008.
Home Office Scientific Development Branch United Kingdom
Hatzigiakoumis DS, Martinotti G, Di Giannantonio M, Janiri L (2011)
Anhedonia and substance dependence: clinical correlates and treat-
ment options. Front Psychiatry 2
Hindocha C, Freeman TP, Schafer G, Gardener C, Das RK, Morgan CJ,
Curran HV (2015a) Acute effects of delta-9-tetrahydrocannabinol,
cannabidiol and their combination on facial emotion recognition: a
randomised, double-blind, placebo-controlled study in cannabis
users. Eur Neuropsychopharmacol 25:325–334
Hindocha C, Shaban ND, Freeman TP, Das RK, Gale G, Schafer G, Falconer
CJ, Morgan CJ, Curran HV (2015b) Associations between cigarette
smoking and cannabis dependence: a longitudinal study of young can-
nabis users in theUnitedKingdom.DrugAlcohol Depend 148:165–171
Hirvonen J, Goodwin R, Li C-T, Terry G, Zoghbi S, Morse C, Pike V,
Volkow N, Huestis M, Innis R (2012) Reversible and regionally
selective downregulation of brain cannabinoid CB1 receptors in
chronic daily cannabis smokers. Mol Psychiatry 17:642–649
Janes AC, Pedrelli P, Whitton AE, Pechtel P, Douglas S, Martinson MA,
Huz I, Fava M, Pizzagalli DA, Evins AE (2015) Reward respon-
siveness varies by smoking status in women with a history of major
depressive disorder. Neuropsychopharmacology 40:1940–1946
Lane SD, Cherek DR, Pietras CJ, Steinberg JL (2005) Performance of
heavy marijuana-smoking adolescents on a laboratory measure of
motivation. Addict Behav 30:815–828
3550 Psychopharmacology (2016) 233:3537–3552
LawnW, Freeman T, Hindocha C, Mokrysz C, Das R, Morgan C, Curran H
(2015) The effects of nicotine dependence and acute abstinence on the
processing of drug and non-drug rewards. Psychopharmacology 232:
2503–2517
Leventhal AM, Kahler CW, Ray LA, Stone K, Young D, Chelminski I,
Zimmerman M (2008) Anhedonia and amotivation in psychiatric
outpatients with fully remitted stimulant use disorder. Am J Addict
17:218–223
Liverant GI, Sloan DM, Pizzagalli DA, Harte CB, Kamholz BW,
Rosebrock LE, Cohen AL, Fava M, Kaplan GB (2014)
Associations among smoking, anhedonia, and reward learning in
depression. Behav Ther 45:651–663
Lubman DI, YücelM, Kettle JW, Scaffidi A,MacKenzie T, Simmons JG,
Allen NB (2009) Responsiveness to drug cues and natural rewards
in opiate addiction: associations with later heroin use. Arch Gen
Psychiatry 66:205–212
Maldonado R, Valverde O, Berrendero F (2006) Involvement of the
endocannabinoid system in drug addiction. Trends Neurosci 29:
225–232
McGlothlin WH, West LJ (1968) The marihuana problem: an overview.
Am J Psychiatr 125:370–378
McPartland JM, Duncan M, Di Marzo V, Pertwee RG (2015) Are
cannabidiol and Δ9‐tetrahydrocannabivarin negative modulators
of the endocannabinoid system? A systematic review. Br J
Pharmacol 172:737–753
Mello NK, Mendelson JH (1985) Operant acquisition of marihuana by
women. J Pharmacol Exp Ther 235:162–171
Mendelson JH, Kuehnle JC, Greenberg I, Mello NK (1976) Operant
acquisition of marihuana in man. J Pharmacol Exp Ther 198:42–53
Miles CG, CONGREW G, Gibbins R, Marshman J, Devenyi P, Hicks R
(1974) An experimental study of the effects of daily cannabis
smoking on behaviour patterns. Acta Pharmacol Toxicol 34:1–44
Miller GA, Chapman JP (2001)Misunderstanding analysis of covariance.
J Abnorm Psychol 110:40–48
Morgan DRK, Joye A, Curran HV, Kamboj SK (2013a) Cannabidiol
reduces cigarette consumption in tobacco smokers: preliminary
findings. Addict Behav 38:2433–2436
Morgan FTP, Schafer GL, Curran HV (2010a) Cannabidiol attenuates the
appetitive effects of Δ9-tetrahydrocannabinol in humans smoking
their chosen cannabis. Neuropsychopharmacology 35:1879–1885
Morgan PE, Schaefer C, Chatten K, Manocha A, Gulati S, Curran HV,
Brandner B, Leweke FM (2013b) Cerebrospinal fluid anandamide
levels, cannabis use and psychotic-like symptoms. Br J Psychiatry
202:381–382
Morgan SG, Freeman TP, Curran HV (2010b) Impact of cannabidiol on
the acute memory and psychotomimetic effects of smoked cannabis:
naturalistic study. Br J Psychiatry 197:285–290
Morgan C, Gardener C, Schafer G, Swan S, Demarchi C, Freeman T,
Warrington P, Rupasinghe I, Ramoutar A, TanN (2012) Sub-chronic
impact of cannabinoids in street cannabis on cognition, psychotic-
like symptoms and psychological well-being. Psychol Med 42:391–
400
Morrison P, Zois V, McKeown D, Lee T, Holt D, Powell J, Kapur S,
Murray R (2009) The acute effects of synthetic intravenous Δ9-
tetrahydrocannabinol on psychosis, mood and cognitive function-
ing. Psychol Med 39:1607–1616
Musty RE, Kaback L (1995) Relationships between motivation and de-
pression in chronic marijuana users. Life Sci 56:2151–2158
Nestor L, Hester R, Garavan H (2010) Increased ventral striatal BOLD
activity during non-drug reward anticipation in cannabis users.
NeuroImage 49:1133–1143
Niv Y, Daw ND, Joel D, Dayan P (2007) Tonic dopamine: opportunity
costs and the control of response vigor. Psychopharmacology 191:
507–520
Parsons LH, Hurd YL (2015) Endocannabinoid signalling in reward and
addiction. Nat Rev Neurosci.
Pergadia ML, Der-Avakian A, D’Souza MS, Madden PA, Heath AC,
Shiffman S, Markou A, Pizzagalli DA (2014) Association between
nicotine withdrawal and reward responsiveness in humans and rats.
JAMA Psychiatry 71:1238–1245
Petitet F, Jeantaud B, Reibaud M, Imperato A, Dubroeucq M-C (1998)
Complex pharmacology of natural cannabinoids: evidence for par-
tial agonist activity of Δ9-tetrahydrocannabinol and antagonist ac-
tivity of cannabidiol on rat brain cannabinoid receptors. Life Sci 63:
PL1–PL6
Pizzagalli DA, Iosifescu D, Hallett LA, Ratner KG, Fava M (2008)
Reduced hedonic capacity in major depressive disorder: evidence
from a probabilistic reward task. J Psychiatr Res 43:76–87
Pizzagalli DA, Jahn AL, O’Shea JP (2005) Toward an objective charac-
terization of an anhedonic phenotype: a signal-detection approach.
Biol Psychiatry 57:319–327
Powell J, Dawkins L, Davis RE (2002) Smoking, reward responsiveness,
and response inhibition: tests of an incentive motivational model.
Biol Psychiatry 51:151–163
Ren Y, Whittard J, Higuera-Matas A, Morris CV, Hurd YL (2009)
Cannabidiol, a nonpsychotropic component of cannabis, inhibits
cue-induced heroin seeking and normalizes discrete mesolimbic
neuronal disturbances. J Neurosci 29:14764–14769
Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson NO, Leonova J,
Elebring T, Nilsson K, Drmota T, Greasley P (2007) The orphan
receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol
152:1092–1101
Schultz W, Dayan P, Montague PR (1997) A neural substrate of predic-
tion and reward. Science 275:1593–1599
Sescousse G, Redouté J, Dreher J-C (2010) The architecture of reward
value coding in the human orbitofrontal cortex. J Neurosci 30:
13095–13104
Sevy S, Smith GS, Ma Y, Dhawan V, Chaly T, Kingsley PB, Kumra S,
Abdelmessih S, Eidelberg D (2008) Cerebral glucose metabolism
and D2/D3 receptor availability in young adults with cannabis de-
pendence measured with positron emission tomography.
Psychopharmacology 197:549–556
Small DM, Jones-Gotman M, Dagher A (2003) Feeding-induced dopa-
mine release in dorsal striatum correlates with meal pleasantness
ratings in healthy human volunteers. Neuroimage 19:1709–1715
Snaith R, Hamilton M, Morley S, Humayan A, Hargreaves D, Trigwell P
(1995) A scale for the assessment of hedonic tone the Snaith-
Hamilton pleasure scale. Br J Psychiatry 167:99–103
Sobell LC, Sobell MB (1992) Timeline follow-back measuring alcohol
consumption. Springer:41–72
Stokes PR, Mehta MA, Curran HV, Breen G, Grasby PM (2009) Can
recreational doses of THC produce significant dopamine release in
the human striatum? NeuroImage 48:186–190
Swift W, Copeland J, Hall W (1998) Choosing a diagnostic cut-off for
cannabis dependence. Addiction 93:1681–1692
TreadwayMT, Bossaller NA, Shelton RC, Zald DH (2012a) Effort-based
decision-making in major depressive disorder: a translational model
of motivational anhedonia. J Abnorm Psychol 121:553
Treadway MT, Buckholtz JW, Cowan RL, Woodward ND, Li R,
Ansari MS, Baldwin RM, Schwartzman AN, Kessler RM, Zald
DH (2012b) Dopaminergic mechanisms of individual differ-
ences in human effort-based decision-making. J Neurosci 32:
6170–6176
Treadway MT, Buckholtz JW, Schwartzman AN, Lambert WE, Zald DH
(2009) Worth the ‘EEfRT’? The effort expenditure for rewards task
as an objective measure of motivation and anhedonia. PLoS One 4:
e6598
Urban NB, SlifsteinM, Thompson JL, XuX, Girgis RR, Raheja S, Haney
M, Abi-Dargham A (2012) Dopamine release in chronic cannabis
users: a [11 c] raclopride positron emission tomography study. Biol
Psychiatry 71:677–683
Psychopharmacology (2016) 233:3537–3552 3551
van Hell HH, Vink M, Ossewaarde L, Jager G, Kahn RS, Ramsey NF
(2010) Chronic effects of cannabis use on the human reward system:
an fMRI study. Eur Neuropsychopharmacol 20:153–163
Volkow ND, Wang GJ, Fischman MW, Foltin RW, Fowler JS, Abumrad
NN, Vitkun S, Logan J, Gatley SJ, Pappas N, Hitzemann R, Shea
CE (1997) Relationship between subjective effects of cocaine and
dopamine transporter occupancy. Nature 386(6627):827–830
Vrieze E, Pizzagalli DA, Demyttenaere K, Hompes T, Sienaert P, de
Boer P, Schmidt M, Claes S (2013) Reduced reward learning
predicts outcome in major depressive disorder. Biol Psychiatry
73:639–645
Wardle MC, Treadway MT, Mayo LM, Zald DH, de Wit H (2011)
Amping up effort: effects of d-amphetamine on human effort-
based decision-making. J Neurosci 31:16597–16602
3552 Psychopharmacology (2016) 233:3537–3552
